Response to combination therapy after relapse in childhood acute lymphocytic leukemia.
D000293:Adolescent; D000741:Anemia, Aplastic / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002490:Central Nervous System / Q000528:radiation effects; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced; D011020:Pneumonia, Pneumocystis / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D012008:Recurrence; D012075:Remission, Spontaneous; D013281:Stomatitis, Aphthous / Q000139:chemically induced; D014750:Vincristine / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D004338:Drug Combinations; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin